{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T15:46:07Z","timestamp":1794584767119,"version":"4.9.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":69,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-026-04989-4","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:05:38Z","timestamp":1781193938000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Extracellular matrix biomarkers of T-cell infiltration and tumor fibrosis predict response to nivolumab\u2009\u00b1\u2009ipilimumab with SBRT in biliary tract cancer: insights from the CheckPAC trial"],"prefix":"10.1186","volume":"24","author":[{"given":"Martin B.","family":"Rasmussen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inna M.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia S.","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susann","family":"Theile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Markussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troels Dreier","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten A.","family":"Karsdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Willumsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"issue":"1","key":"4989_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/CAAC.21871","volume":"75","author":"RL Siegel Mph","year":"2025","unstructured":"Siegel Mph RL, Tyler |, Kratzer B, Giaquinto AN, Hyuna |, Phd S, et al. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10\u201345. https:\/\/doi.org\/10.3322\/CAAC.21871","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"4989_CR2","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1158\/1078-0432.CCR-15-0715","volume":"22","author":"F Sabbatino","year":"2016","unstructured":"Sabbatino F, Villani V, Yearley JH, Deshpande V, Cai L, Konstantinidis IT et al., PD-L1 and HLA class i antigen expression and clinical course of the disease in intrahepatic cholangiocarcinoma. Clinical Cancer Research. 2016;22(2):470-8 https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0715\/115807\/AM\/PD-L1-AND-HLA-CLASS-I-ANTIGEN-EXPRESSION-AND","journal-title":"Clinical Cancer Research"},{"issue":"2","key":"4989_CR3","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/hep.32150","volume":"75","author":"F Carapeto","year":"2022","unstructured":"Carapeto F, Bozorgui B, Shroff RT, Chagani S, Solis Soto L, Foo WC, et al. The immunogenomic landscape of resected intrahepatic cholangiocarcinoma. Hepatology. 2022;75(2):297\u2013308. https:\/\/doi.org\/10.1002\/HEP.32150","journal-title":"Hepatology"},{"key":"4989_CR4","doi-asserted-by":"publisher","unstructured":"Oh DY, Ruth A, Qin S, Chen LT, Okusaka T, Vogel A, et al. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evid. 2022;1(8). https:\/\/doi.org\/10.1056\/EVIDOA2200015","DOI":"10.1056\/EVIDOA2200015"},{"issue":"10391","key":"4989_CR5","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10391):1853\u201365. https:\/\/doi.org\/10.1016\/S0140-6736(23)00727-4","journal-title":"Lancet"},{"issue":"16","key":"4989_CR6","doi-asserted-by":"publisher","first-page":"3428","DOI":"10.1158\/1078-0432.CCR-24-0286","volume":"30","author":"A Markussen","year":"2024","unstructured":"Markussen A, Johansen JS, Larsen FO, Theile S, Hasselby JP, Willemoe GL, et al. Nivolumab with or without Ipilimumab Combined with Stereotactic Body Radiotherapy in Patients with Metastatic Biliary Tract Cancer: A Randomized Phase 2 Study. Clin Cancer Res. 2024;30(16):3428\u201337. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-0286","journal-title":"Clin Cancer Res"},{"key":"4989_CR7","doi-asserted-by":"publisher","unstructured":"Zhu M, Jin M, Zhao X, Shen S, Chen Y, Xiao H, et al. Anti-PD-1 antibody in combination with radiotherapy as first-line therapy for unresectable intrahepatic cholangiocarcinoma. BMC Med. 2024;22(1). https:\/\/doi.org\/10.1186\/S12916-024-03381-4.","DOI":"10.1186\/S12916-024-03381-4"},{"key":"4989_CR8","doi-asserted-by":"publisher","unstructured":"Banales JM, Rodrigues PM, Aff\u00f2 S, Andersen JB, Aspichueta P, Boulter L, et al. Cholangiocarcinoma 2026: status quo, unmet needs and priorities. Nat Reviews Gastroenterol Hepatol 2025. 2025;1\u201332. https:\/\/doi.org\/10.1038\/s41575-025-01153-w.","DOI":"10.1038\/s41575-025-01153-w"},{"issue":"4","key":"4989_CR9","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163","volume":"14","author":"SP Patel","year":"2015","unstructured":"Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14(4):847\u201356. https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-0983","journal-title":"Mol Cancer Ther"},{"issue":"25","key":"4989_CR10","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan M, Hopkins A, Jaffee EM. Tumor Mutational Burden and Response Rate to PD-1 Inhibition. N Engl J Med. 2017;377(25):2500. https:\/\/doi.org\/10.1056\/NEJMC1713444","journal-title":"N Engl J Med"},{"issue":"4","key":"4989_CR11","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1158\/1078-0432.CCR-23-1689\/729513\/","volume":"30","author":"L Paz-Ares","year":"2024","unstructured":"Paz-Ares L, Garassino MC, Chen Y, Reinmuth N, Hotta K, Poltoratskiy A, et al. Durvalumab _ Tremelimumab\u2009+\u2009Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden. Clin Cancer Res. 2024;30(4):824\u201335. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1689\/729513\/AM\/DURVALUMAB-TREMELIMUMAB-PLATINUM-ETOPOSIDE-IN","journal-title":"Clin Cancer Res"},{"issue":"8","key":"4989_CR12","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/J.ANNONC.2024.05.537\/ATTACHMENT\/DDC8D209-4331-47CC-AD80-DE8E0D7751C9","volume":"35","author":"T Powles","year":"2024","unstructured":"Powles T, Albiges L, Bex A, Comperat E, Gr\u00fcnwald V, Kanesvaran R, et al. Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2606. Ann Oncol. 2024;35(8):692\u2013706. https:\/\/doi.org\/10.1016\/J.ANNONC.2024.05.537\/ATTACHMENT\/DDC8D209-4331-47CC-AD80-DE8E0D7751C9\/MMC1.PDF","journal-title":"Ann Oncol"},{"issue":"2","key":"4989_CR13","doi-asserted-by":"publisher","first-page":"10311","DOI":"10.1136\/JITC-2024-010311","volume":"13","author":"DR Gandara","year":"2025","unstructured":"Gandara DR, Agarwal N, Gupta S, Klempner SJ, Andrews MC, Mahipal A, et al. Tumor mutational burden and survival on immune checkpoint inhibition in >\u20098000 patients across 24 cancer types. J Immunother Cancer. 2025;13(2):10311. https:\/\/doi.org\/10.1136\/JITC-2024-010311","journal-title":"J Immunother Cancer"},{"issue":"4","key":"4989_CR14","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.jhep.2019.05.026","volume":"71","author":"G Zhou","year":"2019","unstructured":"Zhou G, Sprengers D, Mancham S, Erkens R, Boor PPC, van Beek AA, et al. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules. J Hepatol. 2019;71(4):753\u201362. https:\/\/doi.org\/10.1016\/j.jhep.2019.05.026","journal-title":"J Hepatol"},{"issue":"4","key":"4989_CR15","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1097\/HEP.0000000000000206","volume":"79","author":"P Cantallops Vil\u00e0","year":"2024","unstructured":"Cantallops Vil\u00e0 P, Ravichandra A, Agirre Lizaso A, Perugorria MJ, Affo S. Heterogeneity, crosstalk, and targeting of cancer-associated fibroblasts in cholangiocarcinoma. Hepatology. 2024;79(4):941\u201358. https:\/\/doi.org\/10.1097\/HEP.0000000000000206","journal-title":"Hepatology"},{"issue":"1","key":"4989_CR16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/S41572-021-00300-2","volume":"7","author":"PJ Brindley","year":"2021","unstructured":"Brindley PJ, Bachini M, Ilyas SI, Khan SA, Loukas A, Sirica AE, et al. Cholangiocarcinoma Nat Rev Dis Primers. 2021;7(1):65. https:\/\/doi.org\/10.1038\/S41572-021-00300-2","journal-title":"Cholangiocarcinoma Nat Rev Dis Primers"},{"key":"4989_CR17","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1146\/annurev-pathmechdis","volume":"13","author":"MH Sherman","year":"2025","unstructured":"Sherman MH, Beatty GL. Tumor Microenvironment in Pancreatic Cancer Pathogenesis and Therapeutic Resistance. Annual Rev Pathology: Mech Disease Annu Rev Pathol Mech Dis. 2025;13:56. https:\/\/doi.org\/10.1146\/annurev-pathmechdis","journal-title":"Annual Rev Pathology: Mech Disease Annu Rev Pathol Mech Dis"},{"issue":"1","key":"4989_CR18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/S40425-019-0556-6\/FIGURES\/6","volume":"7","author":"DE Kuczek","year":"2019","unstructured":"Kuczek DE, Larsen AMH, Thorseth ML, Carretta M, Kalvisa A, Siersb\u00e6k MS, et al. Collagen density regulates the activity of tumor-infiltrating T cells. J Immunother Cancer. 2019;7(1):68. https:\/\/doi.org\/10.1186\/S40425-019-0556-6\/FIGURES\/6","journal-title":"J Immunother Cancer"},{"key":"4989_CR19","doi-asserted-by":"publisher","unstructured":"Nissen NI, Karsdal M, Willumsen N. Collagens and Cancer associated fibroblasts in the reactive stroma and its relation to Cancer biology. J Exp Clin Cancer Res. 2019;38(1). https:\/\/doi.org\/10.1186\/S13046-019-1110-6","DOI":"10.1186\/S13046-019-1110-6"},{"issue":"8","key":"4989_CR20","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1158\/1078-0432","volume":"22","author":"PS Hegde","year":"2016","unstructured":"Hegde PS, Karanikas V, Evers S. The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition. Clin Cancer Res. 2016;22(8):1865\u201374. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1507","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4989_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1476-4598-9-13\/","volume":"9","author":"K Utispan","year":"2010","unstructured":"Utispan K, Thuwajit P, Abiko Y, Charngkaew K, Paupairoj A, Chau-in S, et al. Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker. Mol Cancer. 2010;9(1):13. https:\/\/doi.org\/10.1186\/1476-4598-9-13\/TABLES\/7","journal-title":"Mol Cancer"},{"issue":"S1","key":"4989_CR22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/liv.14098","volume":"39","author":"L Fabris","year":"2019","unstructured":"Fabris L, Perugorria MJ, Mertens J, Bj\u00f6rkstr\u00f6m NK, Cramer T, Lleo A, et al. The tumour microenvironment and immune milieu of cholangiocarcinoma. Liver Int. 2019;39(S1):63\u201378. https:\/\/doi.org\/10.1111\/LIV.14098","journal-title":"Liver Int"},{"issue":"1","key":"4989_CR23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/S12876-025-03645-0\/TABLES\/3","volume":"25","author":"L Kaps","year":"2025","unstructured":"Kaps L, Genc MA, Moehler M, Grabbe S, Schattenberg JM, Schuppan D, et al. Collagen turnover biomarkers to predict outcome of patients with biliary cancer. BMC Gastroenterol. 2025;25(1):53. https:\/\/doi.org\/10.1186\/S12876-025-03645-0\/TABLES\/3","journal-title":"BMC Gastroenterol"},{"issue":"3","key":"4989_CR24","doi-asserted-by":"publisher","first-page":"819","DOI":"10.3390\/CANCERS14030819\/S1","volume":"14","author":"NI Nissen","year":"2022","unstructured":"Nissen NI, Johansen AZ, Chen IM, Johansen JS, Pedersen RS, Hansen CP, et al. Collagen Biomarkers Quantify Fibroblast Activity In Vitro and Predict Survival in Patients with Pancreatic Ductal Adenocarcinoma. Cancers (Basel). 2022;14(3):819. https:\/\/doi.org\/10.3390\/CANCERS14030819\/S1","journal-title":"Cancers (Basel)"},{"issue":"2","key":"4989_CR25","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1136\/JITC-2020-001193","volume":"8","author":"DP Hurkmans","year":"2020","unstructured":"Hurkmans DP, Jensen C, Koolen SLW, Aerts J, Karsdal MA, Mathijssen RHJ, et al. Blood-based extracellular matrix biomarkers are correlated with clinical outcome after PD-1 inhibition in patients with metastatic melanoma. J Immunother Cancer. 2020;8(2):1193. https:\/\/doi.org\/10.1136\/JITC-2020-001193","journal-title":"J Immunother Cancer"},{"issue":"5","key":"4989_CR26","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1002\/ijc.34356","volume":"152","author":"TD Christensen","year":"2023","unstructured":"Christensen TD, Jensen C, Larsen O, Leerh\u00f8y B, Hansen CP, Madsen K, et al. Blood-based tumor fibrosis markers as diagnostic and prognostic biomarkers in patients with biliary tract cancer. Int J Cancer. 2023;152(5):1036\u201349. https:\/\/doi.org\/10.1002\/ijc.34356.","journal-title":"Int J Cancer"},{"issue":"6","key":"4989_CR27","doi-asserted-by":"publisher","first-page":"10739","DOI":"10.1136\/JITC-2024-010739","volume":"13","author":"LA Emens","year":"2025","unstructured":"Emens LA, Moussion C, Hwu P, Gulley JL, Ohashi PS, Bifulco CB, et al. SITC perspective: leveraging patient enrichment biomarkers to accelerate early phase IO drug development. J Immunother Cancer. 2025;13(6):10739. https:\/\/doi.org\/10.1136\/JITC-2024-010739","journal-title":"J Immunother Cancer"},{"key":"4989_CR28","doi-asserted-by":"publisher","first-page":"941","DOI":"10.2147\/CMAR.S474348","volume":"16","author":"L Ni","year":"2024","unstructured":"Ni L, Xu J, Li Q, Ge X, Wang F, Deng X, et al. Focusing on the Immune Cells: Recent Advances in Immunotherapy for Biliary Tract Cancer. Cancer Manag Res. 2024;16:941\u201363. https:\/\/doi.org\/10.2147\/CMAR.S474348","journal-title":"Cancer Manag Res"},{"issue":"10","key":"4989_CR29","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1158\/2326-6066.CIR-16-0013\/470472\/","volume":"4","author":"DB Page","year":"2016","unstructured":"Page DB, Yuan J, Redmond D, Wen YH, Durack JC, Emerson R, et al. Deep sequencing of T-cell receptor DNA as a biomarker of clonally expanded TILs in breast cancer after immunotherapy. Cancer Immunol Res. 2016;4(10):835\u201344. https:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0013\/470472\/AM\/DEEP-SEQUENCING-OF-T-CELL-RECEPTOR-DNA-AS-A","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"4989_CR30","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.3390\/CANCERS14061384","volume":"14","author":"P Gilson","year":"2022","unstructured":"Gilson P, Merlin JL, Harl\u00e9 A. Deciphering tumour heterogeneity: from tissue to liquid biopsy. Cancers 2022;14(6):1384. https:\/\/doi.org\/10.3390\/CANCERS14061384.","journal-title":"Cancers"},{"issue":"19","key":"4989_CR31","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.1158\/0008-5472.CAN-12-2217\/658476\/","volume":"72","author":"C Swanton","year":"2012","unstructured":"Swanton C. Intratumor heterogeneity: Evolution through space and time. Cancer Res. 2012;72(19):4875\u201382. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-2217\/658476\/P\/INTRATUMOR-HETEROGENEITY-EVOLUTION-THROUGH-SPACE","journal-title":"Cancer Res"},{"issue":"21","key":"4989_CR32","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1016\/J.CELL.2021.09.020\/ASSET\/6842C7DF-C7E9-4291-9E73-9FAFBA365018","volume":"184","author":"G Morad","year":"2021","unstructured":"Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021;184(21):5309\u201337. https:\/\/doi.org\/10.1016\/J.CELL.2021.09.020\/ASSET\/6842C7DF-C7E9-4291-9E73-9FAFBA365018\/MAIN.ASSETS\/GR2.JPG","journal-title":"Cell"},{"issue":"6","key":"4989_CR33","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/J.IMMUNI.2014.11.012\/ATTACHMENT\/4569E285-96E6-4E00-97C4-2B2D2BB5DDF5","volume":"41","author":"MD Prakash","year":"2014","unstructured":"Prakash MD, Munoz MA, Jain R, Tong PL, Koskinen A, Regner M, et al. Granzyme B promotes cytotoxic lymphocyte transmigration via basement membrane remodeling. Immunity. 2014;41(6):960\u201372. https:\/\/doi.org\/10.1016\/J.IMMUNI.2014.11.012\/ATTACHMENT\/4569E285-96E6-4E00-97C4-2B2D2BB5DDF5\/MMC10.PDF","journal-title":"Immunity"},{"issue":"10","key":"4989_CR34","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.3390\/CANCERS12102786","volume":"12","author":"C Jensen","year":"2020","unstructured":"Jensen C, Sinkeviciute D, Madsen DH, \u00d6nnerfjord P, Hansen M, Schmidt H, et al. Granzyme B Degraded Type IV Collagen Products in Serum Identify Melanoma Patients Responding to Immune Checkpoint Blockade. Cancers. 2020;12(10):2786. https:\/\/doi.org\/10.3390\/CANCERS12102786","journal-title":"Cancers"},{"issue":"7","key":"4989_CR35","doi-asserted-by":"publisher","first-page":"616","DOI":"10.3109\/1354750X.2011.620628","volume":"16","author":"DJ Leeming","year":"2011","unstructured":"Leeming DJ, He Y, Veidal SS, Nguyen QHT, Larsen DV, Koizumi M, et al. A novel marker for assessment of liver matrix remodeling: An enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M). Biomarkers. 2011;16(7):616\u201328. https:\/\/doi.org\/10.3109\/1354750X.2011.620628","journal-title":"Biomarkers"},{"issue":"3","key":"4989_CR36","first-page":"303","volume":"5","author":"MJ Nielsen","year":"2013","unstructured":"Nielsen MJ, Nedergaard AF, Sun S, Veidal SS, Larsen L, Zheng Q, et al. The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters. Am J Transl Res. 2013;5(3):303.","journal-title":"Am J Transl Res"},{"issue":"10\u201311","key":"4989_CR37","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.clinbiochem.2010.03.012","volume":"43","author":"N Barascuk","year":"2010","unstructured":"Barascuk N, Veidal SS, Larsen L, Larsen DV, Larsen MR, Wang J, et al. A novel assay for extracellular matrix remodeling associated with liver fibrosis: An enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen. Clin Biochem. 2010;43(10\u201311):899\u2013904. https:\/\/doi.org\/10.1016\/J.CLINBIOCHEM.2010.03.012","journal-title":"Clin Biochem"},{"issue":"12","key":"4989_CR38","doi-asserted-by":"publisher","first-page":"e84934","DOI":"10.1371\/journal.pone.0084934","volume":"8","author":"JM Sand","year":"2013","unstructured":"Sand JM, Larsen L, Hogaboam C, Martinez F, Han ML, Larsen MR, et al. MMP Mediated Degradation of Type IV Collagen Alpha 1 and Alpha 3 Chains Reflects Basement Membrane Remodeling in Experimental and Clinical Fibrosis \u2013 Validation of Two Novel Biomarker Assays. PLoS ONE. 2013;8(12):e84934. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0084934","journal-title":"PLoS ONE"},{"issue":"12","key":"4989_CR39","doi-asserted-by":"publisher","first-page":"e0144525","DOI":"10.1371\/journal.pone.0144525","volume":"10","author":"S Sun","year":"2015","unstructured":"Sun S, Henriksen K, Karsdal MA, Byrjalsen I, Rittweger J, Armbrecht G, et al. Collagen Type III and VI Turnover in Response to Long-Term Immobilization. PLoS ONE. 2015;10(12):e0144525. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0144525","journal-title":"PLoS ONE"},{"key":"4989_CR40","doi-asserted-by":"publisher","unstructured":"Jensen C, Madsen DH, Hansen M, Schmidt H, Svane IM, Karsdal MA, et al. Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients. J Immunother Cancer. 2018;6(1). https:\/\/doi.org\/10.1186\/S40425-018-0474-Z","DOI":"10.1186\/S40425-018-0474-Z"},{"issue":"5","key":"4989_CR41","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.ejso.2019","volume":"46","author":"H Jansson","year":"2020","unstructured":"Jansson H, Cornillet M, Bj\u00f6rkstr\u00f6m NK, Sturesson C, Sparrelid E. Prognostic value of preoperative inflammatory markers in resectable biliary tract cancer \u2013 Validation and comparison of the Glasgow Prognostic Score and Modified Glasgow Prognostic Score in a Western cohort. Eur J Surg Oncol. 2020;46(5):804\u201310. https:\/\/doi.org\/10.1016\/j.ejso.2019.12.008","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"4989_CR42","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.21873\/ANTICANRES.12412","volume":"38","author":"N Okano","year":"2018","unstructured":"Okano N, Kasuga A, Kawai K, Yamauchi Y, Kobayashi T, Naruge D, et al. The Modified Glasgow Prognostic Score in Patients with Gemcitabine-refractory Biliary Tract Cancer. Anticancer Res. 2018;38(3):1755\u201361. https:\/\/doi.org\/10.21873\/ANTICANRES.12412","journal-title":"Anticancer Res"},{"issue":"5","key":"4989_CR43","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.jhep.2021.12.010","volume":"76","author":"L Izquierdo-Sanchez","year":"2022","unstructured":"Izquierdo-Sanchez L, Lamarca A, La Casta A, Buettner S, Utpatel K, Kl\u00fcmpen HJ, et al. Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. J Hepatol. 2022;76(5):1109\u201321. https:\/\/doi.org\/10.1016\/j.jhep.2021.12.010","journal-title":"J Hepatol"},{"key":"4989_CR44","doi-asserted-by":"publisher","unstructured":"Herzog BH, Baer JM, Borcherding N, Kingston NL, Belle JI, Knolhoff BL, et al. Tumor-associated fibrosis impairs immune surveillance and response to immune checkpoint blockade in non\u2013small cell lung cancer. Sci Transl Med. 2023;15(699). https:\/\/doi.org\/10.1126\/scitranslmed.adh8005.","DOI":"10.1126\/scitranslmed.adh8005"},{"key":"4989_CR45","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.matbio.2023.04.002","volume":"119","author":"A Naik","year":"2023","unstructured":"Naik A, Leask A. Tumor-associated fibrosis impairs the response to immunotherapy. Matrix Biol. 2023;119:125\u201340. https:\/\/doi.org\/10.1016\/J.MATBIO.2023.04.002","journal-title":"Matrix Biol"},{"issue":"8","key":"4989_CR46","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/S00262-017-2003-1","volume":"66","author":"H Jiang","year":"2017","unstructured":"Jiang H, Hegde S, DeNardo DG. Tumor-associated fibrosis as a regulator of tumor immunity and response to immunotherapy. Cancer Immunol Immunother. 2017;66(8):1037. https:\/\/doi.org\/10.1007\/S00262-017-2003-1","journal-title":"Cancer Immunol Immunother"},{"issue":"24","key":"4989_CR47","doi-asserted-by":"publisher","first-page":"e2500019122","DOI":"10.1073\/PNAS.2500019122\/SUPPL_FILE\/PNAS.2500019122.SD21","volume":"122","author":"M Wang","year":"2025","unstructured":"Wang M, Wang Y, Pan X, Wang B, Wang Y, Luo X, et al. Acquired resistance to immunotherapy by physical barriers with cancer cell\u2013expressing collagens in non\u2013small cell lung cancer. Proc Natl Acad Sci U S A. 2025;122(24):e2500019122. https:\/\/doi.org\/10.1073\/PNAS.2500019122\/SUPPL_FILE\/PNAS.2500019122.SD21.XLSX","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"4989_CR48","doi-asserted-by":"publisher","first-page":"e0175582","DOI":"10.1371\/journal.pone.0175582","volume":"12","author":"J Parkin","year":"2017","unstructured":"Parkin J, Des, San Antonio JD, Persikov AV, Dagher H, Dalgleish R, Jensen ST, et al. The coll\u03b1gen III fibril has a flexi-rod structure of flexible sequences interspersed with rigid bioactive domains including two with hemostatic roles. PLoS ONE. 2017;12(7):e0175582. https:\/\/doi.org\/10.1371\/journal.pone.0175582.","journal-title":"PLoS ONE"},{"issue":"3","key":"4989_CR49","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1055\/S-0040-1705109","volume":"40","author":"L Fabris","year":"2020","unstructured":"Fabris L, Cadamuro M, Cagnin S, Strazzabosco M, Gores GJ. Liver Matrix in Benign and Malignant Biliary Tract Disease. Semin Liver Dis. 2020;40(3):282\u201397. https:\/\/doi.org\/10.1055\/S-0040-1705109","journal-title":"Semin Liver Dis"},{"issue":"2","key":"4989_CR50","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jhep.2020.03.008","volume":"73","author":"R Montal","year":"2020","unstructured":"Montal R, Sia D, Montironi C, Leow WQ, Esteban-Fabr\u00f3 R, Pinyol R, et al. Molecular Classification and Therapeutic Targets in Extrahepatic Cholangiocarcinoma. J Hepatol. 2020;73(2):315. https:\/\/doi.org\/10.1016\/J.JHEP.2020.03.008","journal-title":"J Hepatol"},{"issue":"7","key":"4989_CR51","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41416-020-0744-7","volume":"122","author":"T Yamanaka","year":"2020","unstructured":"Yamanaka T, Harimoto N, Yokobori T, Muranushi R, Hoshino K, Hagiwara K, et al. Nintedanib inhibits intrahepatic cholangiocarcinoma aggressiveness via suppression of cytokines extracted from activated cancer-associated fibroblasts. Br J Cancer 2020. 2020;122(7):7. https:\/\/doi.org\/10.1038\/s41416-020-0744-7","journal-title":"Br J Cancer 2020"},{"issue":"10","key":"4989_CR52","doi-asserted-by":"publisher","first-page":"4564","DOI":"10.7150\/thno.68972","volume":"12","author":"Y Wu","year":"2022","unstructured":"Wu Y, Yi Z, Li J, Wei Y, Feng R, Liu J, et al. FGFR blockade boosts T cell infiltration into triple-negative breast cancer by regulating cancer-associated fibroblasts. Theranostics. 2022;12(10):4564. https:\/\/doi.org\/10.7150\/THNO.68972","journal-title":"Theranostics"},{"issue":"8","key":"4989_CR53","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/bjc.2017.270","volume":"117","author":"M Gabasa","year":"2017","unstructured":"Gabasa M, Ikemori R, Hilberg F, Reguart N, Alcaraz J. Nintedanib selectively inhibits the activation and tumour-promoting effects of fibroblasts from lung adenocarcinoma patients. Br J Cancer. 2017;117(8):1128\u201338. https:\/\/doi.org\/10.1038\/bjc.2017.270","journal-title":"Br J Cancer"},{"issue":"6","key":"4989_CR54","doi-asserted-by":"publisher","first-page":"103488","DOI":"10.1016\/j.esmoop.2024.103488","volume":"9","author":"A Vogel","year":"2024","unstructured":"Vogel A, Sahai V, Hollebecque A, Vaccaro GM, Melisi D, Al Rajabi RM, et al. An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202. ESMO Open. 2024;9(6):103488. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103488","journal-title":"ESMO Open"},{"issue":"3","key":"4989_CR55","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMOA2206834\/SUPPL_FILE\/","volume":"388","author":"L Goyal","year":"2023","unstructured":"Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, et al. Futibatinib for FGFR2 -Rearranged Intrahepatic Cholangiocarcinoma. N Engl J Med. 2023;388(3):228\u201339. https:\/\/doi.org\/10.1056\/NEJMOA2206834\/SUPPL_FILE\/NEJMOA2206834_DATA-SHARING.PDF","journal-title":"N Engl J Med"},{"issue":"5","key":"4989_CR56","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21(5):671\u201384. https:\/\/doi.org\/10.1016\/S1470-2045(20)30109-1","journal-title":"Lancet Oncol"},{"issue":"4","key":"4989_CR57","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/gutjnl-2021-326514","volume":"72","author":"MA Martin-Serrano","year":"2023","unstructured":"Martin-Serrano MA, Kepecs B, Torres-Martin M, Bramel ER, Haber PK, Merritt E, et al. Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications. Gut. 2023;72(4):736\u201348. https:\/\/doi.org\/10.1136\/GUTJNL-2021-326514","journal-title":"Gut"},{"issue":"6","key":"4989_CR58","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1007\/S12094-024","volume":"27","author":"C Jensen","year":"2025","unstructured":"Jensen C, Maarup S, Poulsen HS, Hasselbalch B, Karsdal M, Svane IM, et al. Degradation fragments of Tau and type IV collagen as serum biomarkers in patients with recurrent glioblastoma treated with nivolumab and bevacizumab. Clin Transl Oncol. 2025;27(6):2761\u20137. https:\/\/doi.org\/10.1007\/S12094-024-03775-Z","journal-title":"Clin Transl Oncol"},{"key":"4989_CR59","doi-asserted-by":"publisher","unstructured":"Rizzo A, Erul E, Guven DC, Sahin TK, Monteiro FSM, De Luca R et al. Immunotherapy in biliary tract cancer: effective but not enough? Expert Rev Clin Pharmacol 2025 Nov 16. https:\/\/doi.org\/10.1080\/17512433.2025.2590695","DOI":"10.1080\/17512433.2025.2590695"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-04989-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04989-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04989-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:35:45Z","timestamp":1787099745000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-04989-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4989"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-04989-4","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"4 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Regional Ethics Committee (no. H-16031247) and the Danish Medicine Agency (EudraCT no. 2016-001883-12). All patients provided written informed consent. All patients were also included in the Danish CHOCA study \u201cIdentification of New Biomarkers for Patients with Cholangiocarcinoma and Gallbladder Cancer\u201d (NCT05184400), approved by the Danish Ethics Committee (H-3-2014-055) and the Danish Data Protection Agency (j.nr. HEH 2014-097, I-Suite j.nr. 03260, PACTIUS-2020-797).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have agreed to the submission and publication of this research.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.B.R., M.A.K., and N.W. are employed at Nordic Bioscience. M.A.K. and N.W. have stocks in Nordic Bioscience. Besides these, the authors declare no conflict of interest.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"452"}}